Cancer News and Research

Latest Cancer News and Research

pIMAGO nanopolymer can test cancer drug efficacy against biochemical processes

A Purdue University scientist's nanopolymer would make it easier and cheaper for drug developers to test the effectiveness of a widely used class of cancer inhibitors.

17 Mar 2011

Inovio signs agreement with OncoSec to sell non-DNA cancer vaccine technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has signed an agreement with OncoSec Medical Inc. providing for the sale to OncoSec of certain non-DNA vaccine technology and intellectual property relating to electroporation technology useful for electrochemical and cytokine based immune therapies for treating solid tumors.

17 Mar 2011

PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting

PsiOxus Therapeutics, Ltd. announced initiation of a Phase II study of MT-102, a small molecule therapeutic for the treatment of cancer- and age-related wasting. MT-102 is being developed to reverse the effects of cachexia, a wasting disease that accompanies cancer, heart failure, COPD, renal failure, cirrhosis and rheumatoid arthritis, and that is associated with significant morbidity and mortality.

17 Mar 2011

Scientist suggests breaking tangled mucus barrier can help treat cancer

Measuring the mechanical strength of cancer cell mucus layers provides clues about better ways to treat cancer, and also suggests why some cancer cells are more resistant to drugs than others, according to Kai-tak Wan, associate professor of engineering at Northeastern University, Boston, Mass.

17 Mar 2011

Researchers update 'Hallmarks of Cancer' seminal review

Renowned cancer researchers Robert Weinberg, a Founding Member of Whitehead Institute, and Douglas Hanahan, Director of the Swiss Institute for Experimental Cancer Research have updated their seminal review, "Hallmarks of Cancer," which has influenced the study of cancer and the development of therapeutics for more than a decade.

17 Mar 2011

Leading cancer center to acquire GammaMed brachytherapy from Varian

Cancer patients in China will gain access to Varian's state-of-the-art cancer care with the announcement that a leading cancer center is acquiring a GammaMed brachytherapy afterloader from Varian Medical Systems.

17 Mar 2011

Laser light can kill cancer cells by pumping drugs into them

Shining a laser light on cells and then clicking off the light makes the cells "breathe in" surrounding water, providing a potentially powerful delivery system for chemotherapy drugs, as well as a non-invasive way to target anti-Alzheimer's medicines to the brain. That's the conclusion of a report in ACS's The Journal of Physical Chemistry Letters.

17 Mar 2011

African-American women who live in more dense urban areas gain less weight

Researchers from Boston University School of Medicine's Slone Epidemiology Center have found that African-American women who live in more densely populated urban areas gain less weight than those in more sprawling auto-oriented areas.

17 Mar 2011

Expert discusses certain measures that can help prevent HAI spread

Healthcare-associated infections represent a growing concern for both patients and healthcare providers across the nation. The Centers for Disease Control and Prevention estimates that approximately 1.7 million HAIs occur each year and contribute to the death of 99,000.

17 Mar 2011

New lozenge clinical trial for dry mouth treatment

A clinical trial using an all-natural lozenge to treat dry mouth, a condition that impacts 40 percent of American adults, is under way at Georgia Health Sciences University College of Dental Medicine.

17 Mar 2011

New study: Positive outcomes from gene therapy trial in patients with Parkinson's

A multi-center gene therapy trial for patients with advanced Parkinson's disease demonstrated reduced symptoms of the progressive movement disorder, according to a new study published in Lancet Neurology.

17 Mar 2011

HGSI, FivePrime enter agreement to develop, commercialize FP-1039 for multiple cancers

Human Genome Sciences, Inc. and FivePrime Therapeutics, Inc. announced today that they have entered into an agreement to develop and commercialize FivePrime's FP-1039 product for multiple cancers.

17 Mar 2011

Personalized dendritic cell vaccine may increase median survival in mesenchymal glioblastoma patients

A dendritic cell vaccine personalized for each individual based on the patient's own tumor may increase median survival time in those with a deadly form of brain cancer called glioblastoma, an early phase study at UCLA's Jonsson Comprehensive Cancer Center has found.

17 Mar 2011

Digna Biotech and Biotecnol to begin CT-I Phase I trial in healthy volunteers

Digna Biotech and Biotecnol announced today that the Spanish Regulatory Medicine Agency has authorized the start of a Phase I Clinical Trial in healthy volunteers for Cardiotrophin-I.

17 Mar 2011

Skyline Diagnostics launches unique test to detect patients with AML

Each year over eight million people die of cancer worldwide. Patients' chances of survival vary widely: depending on the type of cancer involved, the stage at which it is diagnosed and the speed with which appropriate treatment is launched.

17 Mar 2011

Specific type of selenium supplement may help prevent cancer

Scientists are reporting that the controversy surrounding whether selenium can fight cancer in humans might come down to which form of the essential micronutrient people take.

17 Mar 2011

Research highlights new parameters for HIV study

A research article co-authored by Brenna Anderson, MD, director of Reproductive Infectious Diseases Consultation in the Division of Maternal-Fetal Medicine at Women & Infants Hospital of Rhode Island, was included in the recently published special issue of the American Journal of Reproductive Immunology.

17 Mar 2011

Heart disease: The largest killer in Australia

According to a new federal government report, heart disease is the biggest killer in Australia, causing nearly 50,000 deaths a year.

16 Mar 2011

MorphoSys inks manufacturing agreement with Boehringer Ingelheim

MorphoSys AG and Boehringer Ingelheim announced today the signing of a biopharmaceutical manufacturing agreement for therapeutic antibodies. The agreement covers the process development and manufacturing of additional clinical material for MorphoSys's proprietary MOR208 program and other drug candidates. MOR208, a potent monoclonal anti-CD19 antibody, is in development for the treatment of chronic lymphocytic leukemia and potentially other B-cell malignancies. The program is currently being evaluated in a phase 1 clinical trial in the USA by MorphoSys's partner Xencor Inc.

16 Mar 2011

Genesis Biopharma to establish Adoptive Cell Immunotherapy based therapeutic development program

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, today announced it is expanding its therapeutic strategy to include active immunotherapies to treat various cancers. The Company will focus on establishing a therapeutic development program based on Adoptive Cell Immunotherapy.

16 Mar 2011